Loading clinical trials...
Loading clinical trials...
Prospective, Open-Label, Non-Comparative, Multicenter Study for the Secondary Prophylaxis of Invasive Fungal Infections (IFI) With Voriconazole in Patients With Allogeneic Stem Cell Transplants (SCT).
To prevent recurrence of invasive fungal infection in patients with allogeneic stem cell transplants
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Pfizer Investigational Site
Leuven, Belgium
Pfizer Investigational Site
Marseille, Cedex 09, France
Pfizer Investigational Site
Créteil, France
Pfizer Investigational Site
Nantes, France
Pfizer Investigational Site
Pessac, France
Pfizer Investigational Site
Strasbourg, France
Pfizer Investigational Site
Cologne, Germany
Pfizer Investigational Site
Mainz, Germany
Pfizer Investigational Site
Würzburg, Germany
Pfizer Investigational Site
Lisbon, Lisbon District, Portugal
Start Date
February 1, 2005
Primary Completion Date
April 1, 2008
Completion Date
April 1, 2008
Last Updated
October 6, 2009
45
ACTUAL participants
voriconazole
DRUG
Lead Sponsor
Pfizer
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions